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Abstract
Background
Mantle cell lymphoma (MCL) is currently an incurable entity, and new therapeutic approaches are needed. We have applied a 
high-throughput phospho-proteomic technique to MCL cell lines to identify activated pathways and we have then validated our 
data in both cell lines and tumor tissues.
Methods
PhosphoScan analysis was performed on MCL cell lines. Results were validated by flow cytometry and western blotting. 
Functional validation was performed by blocking the most active pathway in MCL cell lines.
Results
PhosphoScan identified more than 300 tyrosine-phosporylated proteins, among which many protein kinases. The most abundant 
peptides belonged to proteins connected with B-cell receptor (BCR) signaling. Active BCR signaling was demonstrated by flow 
cytometry in MCL cells and by western blotting in MCL tumor tissues. Blocking BCR signaling by Syk inhibitor piceatannol 
induced dose/time-dependent apoptosis in MCL cell lines, as well as several modifications in the phosphorylation status of BCR 
pathway members and a collapse of cyclin D1 protein levels.
Conclusion
Our data support a pro-survival role of BCR signaling in MCL and suggest that this pathway might be a candidate for therapy. 
Our findings also suggest that Syk activation patterns might be different in MCL compared to other lymphoma subtypes.
Electronic supplementary material
The online version of this article (doi:10.1007/s13402-011-0019-7) contains supplementary material, which is available to 
authorized users.
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Introduction
Mantle cell lymphoma constitutes about 6% of non-Hodgkin lymphoma in the western world [1]. It shows a characteristic 
clinical behavior with initial response to therapy followed by relapses and death in 3–5 years. Aggressive therapeutic regimens 
are promising, but to-date MCL is still considered incurable, with the exception of a small group of long-surviving patients. In 
recent years, many high-throughput techniques have been applied to MCL in order to gain insights into its pathogenesis, and to 
discover suitable therapeutic targets [2–9]. These studies have clarified a role for increased proliferation and resistance to 
apoptosis in MCL, involving several signaling pathways.
A few studies from our group and also from others have attempted the study of MCL from a proteomic point of view [10–18]. 
Some of these studies were mainly focused on the diagnostic implementation of proteomic techniques [14–16], while other were 
more focused on the pathogenetic mechanisms [12, 18–20]. These studies have identified single up-regulated proteins in MCL 
compared to tonsil B-cells [12], or several proteins up-regulated in MCL cell lines compared to FL-derived cell lines followed by 
network analysis [21]. More recently, a proteomic study focused on the plasma membrane proteome of leukemic MCL and 
compared it to normal B-cells [19]; this study identified several alterations in the proteome of MCL lipid rafts that might have 
therapeutic potential. In a previous study we have focused our attention on the phospho-proteome of several MCL cell lines by 
using immobilized metal affinity chromatography (IMAC) pre-fractionation (a column-based technique that selectively enriches 
all phospho-proteins by a reversible binding to metal oxydes), followed by 2D-PAGE/MS [20]. In that study we identified 
several activated pathways that might reflect the biology of MCL, including the alternative NF-kB pathway, the mTOR pathway 
and the mitochondrial pathway. In the present work we have used a complementary approach, called PhosphoScan, that involves 
an immunoprecipitation of peptides by using an anti-phosphotyrosine antibody followed by capillary electrophoresis and MS 
identification of eluted peptides [22]. Compared to IMAC, PhosphoScan should better dissect phosphorylation profiles, 
specifically identifying tyrosine-phosphorylated peptides. This approach has already been successfully used in the phospho-
profiling of primary [23] and metastatic [24] lung cancer, in acute leukemia samples [25], in Bcr/Abl positive cell lines [26], 
AML cell lines [27] and Hodgkin lymphoma cell lines [28]. Since tyrosine phosphorylation regulates the activity of many 
proteins, the PhosphoScan approach can provide a picture of the most active pathways in the analyzed samples. Moreover, since 
many kinases are themselves activated by tyrosine phosphorylation, the profile of active kinases is also provided; often these 
kinases are driving cell proliferation and survival, and are therefore candidate targets for therapy.
In the current work, we used this approach to recognize the most represented activated pathways in MCL cell lines. We then 
verified the presence of these activated molecules in MCL cell lines and tumor tissues. We subsequently explored the functional 
role of the most activated pathway in MCL cell lines by inhibition experiments.
Results and discussion
In the current paper we describe the results obtained from the application of PhosphoScan to MCL cells. This is to our 
knowledge the first use of this technique in MCL; we report a large amount of data with precise identification of phosphorylation 
sites for each protein, some of which novel.
PhosphoScan analysis identifies the tyrosine-activated phosphoproteome of MCL cell lines and identifies 
B-cell receptor signaling as the most active pathway
PhosphoScan analysis identified 421 unique tyrosine-phosphorylated peptides, corresponding to 341 proteins, ranked by overall 
abundance in Table 1 (for a complete list of peptides and complete MS information see Supplemental Table 1). Interestingly, 
several identified proteins mapped to cytogenetic loci that have been reported to be altered in MCL [29–31]. Among these, 
several activated protein kinases were identified (Fig. 1), that are therefore appealing as potential therapeutic targets. 
Table 1
Top 50 phospho-peptides identified (number of phospho peptides corresponding to the specific protein is 
reported. For complete list and exact phosphorylation sites, see suppl. Table 1)
Fig. 1
List of protein kinases identified by the PhosphoScan approach, ranked by overall abundance in the four MCL cell 
lines analyzed. Color intensity proportional to the number of peptides (see figure for color corresponding to the 
average number of peptides ...
The three most represented phospho-peptides are cyclin-dependent kinases Cdc2, CDK2 and CDK3. Cdc2 (CDK1) is actually 
part of the proliferation signature able to predict prognosis in MCL [8] and has also been validated at the immunohistochemical 
level [32]. CDK2 gains have been detected in MCL in a variable proportion of cases [30, 31, 33], and have been associated with 
a poor prognosis [33]. CDK3 is less studied compared to other cyclin-dependent kinases, but its locus has also been reported as 
subject to gains [31, 34]. Its involvement in MCL is a novel finding, although the role of CDK3 as an oncogene has been 
demonstrated in other models [35, 36].
Syk and many other BCR pathway members were then found. Many kinases belonging to this pathway (e.g. Syk, Lyn, Hck, Btk, 
PKC-delta), were among the most represented phospho-peptides identified by the PhosphoScan approach, and this was 
confirmed when looking for non-random enrichment of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways [37] 
compared to the hypothesis of random distribution. This analysis showed that (using a cutoff value of more than five total 
peptides), the most enriched pathway was hsa04662:B cell receptor signaling pathway (17.16-fold enrichment) (for complete 
data see Supplemental Table 2).
Many of the proteins belonging to the most enriched pathways were either present in different pathways (redundant) or are 
functionally connected. Manual annotation by literature search revealed that several of these, in the topmost part of the ranking, 
were connected to BCR signaling, even if not present in the canonical KEGG BCR pathway (Table 1 and Fig. 2). 
Fig. 2
Simplified diagram showing some of the identified BCR pathway members. In red, activating members; in green, 
inhibiting members; for some members the precise final effect is not clear; in grey, other proteins known to be 
present but not identified. Full ...
The presence of active B-cell receptor signaling is validated in MCL cell lines and tissues
To further verify the functional role of BCR signaling in MCL, we analyzed the phosphorylation status of Syk, Lyn, Btk, Blnk 
and GSK3alfa/beta in MCL cell lines. Although not present in the top 50 phospho-peptides, Blnk was investigated because it is 
considered a classical downstream molecule of the BCR pathway. The presence of basal levels of phospho-Syk Y525 and Y323, 
as well as of phospho-Blnk (Y84) was verified by flow cytometry (Fig. 3). By this technique, we could detect no basal levels of 
phospho-Syk Y352. In addition basal levels of phospho-Lyn (Y396 and Y507) and also of downstream effectors phospho-Btk 
(S180) and phospho-GSK3alfa/beta (S9/21) were demonstrated by flow cytometry (Supplemental Figure 1). BCR pathway 
activation in cell lines is somehow intriguing since it is present in absence of an appropriate antigen stimulation, and is therefore 
probably self-sustained by tumor cells, either by side-by-side activation or by auto-activation. 
Fig. 3
Analysis of basal levels of phosphorylated Syk and Blnk residues by flow cytometry. In grey, isotypic control; in 
red, basal levels. On the X axis, arbitrary fluorescence units (log scale); on the Y axis, cell count
In order to verify whether we could find this activation in MCL tumors as well, we resorted to western blotting analysis of 
phosphorylated forms of BCR pathway members. This analysis showed that the activated forms of Syk (in 5/6 cases, 83%), Lyn 
(in 6/6 cases, 100%), and Blnk (in 6/6 cases, 100%) were present also in MCL tumor tissues (Fig. 4), therefore supporting the in 
vivo role of active BCR signaling; as far as we know, this is the first report of the presence of active (phosphorylated) BCR 
pathway members in MCL tissues. 
Fig. 4
Western blotting analysis of MCL tissues. The presence of phospho-Syk (Y525), phospho-Lyn (Y396) and 
phospho-Blnk (Y84) is shown in six MCL tumor tissues. Cases 1, 2, 5 and 6 were classical MCL, while cases 3 
and 4 were blastoid variants
The activation of the BCR pathway in MCL has been hypothesized in a previous paper based on cytogenetic and RNA studies 
[6], but to our knowledge this is the first protein-based and data-driven study that supports this hypothesis. Another proteomic 
study focusing only on the plasma membrane [19] showed an abnormal association of PKCbeta to the cell membrane in MCL 
leukemic cells, indirectly supporting an active BCR signaling.
Recent studies have shown the importance of tonic BCR signaling in DLBCL [38, 39] and B-CLL [40], with a basal activation of 
phospho-Syk residue Y352, while Y525 was detected only after BCR cross-linking. The presence of significant basal levels of 
phospho-Syk Y525 and Y323, with no detectable phospho-Syk Y352 in basal conditions in MCL cells are not concordant with 
what has been reported in B-CLL and DLBCL [40], and suggest a different pattern of activation of BCR signaling in MCL.
A recent report of a phase 1/2 clinical trial of fostamatinib disodium, the first clinically available oral Syk inhibitor, in patients 
with recurrent B-cell non-Hodgkin lymphoma, showed that only 1 in 9 MCL showed some response [41]. Several explanations 
might be possible for this low response rate. First, the specificity of this drug for Syk has been recently questioned [39]. Second, 
relapsed lymphomas might have evolved into BCR-independent clones (such as the cell line Rec-1). Third, since our data 
support the hypothesis that the activation pattern of Syk in MCL is different from B-CLL and DLBCL, it is possible that this 
phenomenon influences the response to fostamatinib.
Inhibition of Syk induces apoptosis in MCL cell lines
Since the proteins belonging to the BCR signaling pathway were shown to be active, we tested the effect of the blockade of this 
pathway on MCL cells. For this purpose, Syk activity was inhibited by a widely used inhibitor, piceatannol [42–45], a natural 
stilbene also resulting from the hepatic metabolism of resveratrol, a compound found to be pro-apoptotic for the MCL cell line 
Jeko-1 [11]. The Rec-1 cell line showed a marked hypersensitivity to DMSO, and it was deemed unfit for further experimental 
work, which was conducted on less sensitive cell lines.
Piceatannol induced apoptosis in MCL cell lines Jeko-1, UPN-1, Mino, Maver-1 and Granta-519, as evidenced by Annexin V 
staining, with a LD50 varying from 9.50 μM to 28.91 μM at 24 h and 5.51 μM and 23.54 μM at 48 h (Supplemental Table 3 and 
Fig. 5). 
Fig. 5
Induction of apoptosis in MCL cell lines. Upper panel shows the percentage of live cells (Y axis) in function of the 
piceatannol concentration (X axis) at 24 h. Lower panel shows the same variables at 48 h of treatment. Annexin V 
staining ...
Interestingly, Jeko-1, which is very sensitive to piceatannol, also shows the highest number of phospho-peptides belonging to the 
BCR pathway (Supplemental Table 4).
Apoptosis was dose and time dependent being visible after 4 h of treatment in Jeko-1, but only after 16 h in MAVER-1 (data not 
shown).
Inhibition of Syk down-regulates Cyclin D1 protein levels
Cyclin D1 protein levels were massively down-regulated in treated cells, as densitometric analysis showed a drop by 85 to 90% 
compared to untreated cells (Supplemental Figure 2). The corresponding CCND1 mRNA was down-regulated after piceatannol 
treatment, showing 22% to 71% decrease (after normalization) in five tested cell lines (Supplemental Figure 3). This decrease 
was however significant only in three cell lines, namely UPN-1 (54% decrease; p = 0.047), Granta-519 (71% decrease; p = 
0.0078) and MAVER-1 (69% decrease; p = 0.008).
This finding is interesting, considering that the CCND1 gene is translocated under the control of a strong enhancer such as the 
Igμ enhancer. A hypothetical scenario could be hypothesized in which BCR signaling and CCND1 gene transcription are 
connected, possibly via Syk. Cyclin D1 has been shown to be a Syk target gene in breast cancer and other cells [46]. It is possible 
that CCND1 gene transcription is directly repressed by Syk, in accordance to the fact that normal B cells show very low levels of 
this protein and at the same time nuclear localization of Syk. As previously stated, in support of this hypothesis Syk acts as a 
transcriptional repressor of the CCND1 gene in breast carcinoma cells, and this activity is necessary for its tumor-suppressor 
function [46]. One hypothesis is that in MCL cells Syk might act via Stat3, a known CCND1 gene transcription inducer, as 
suggested by a recent publication [47]. In support of this hypothesis, the phosphorylation of Stat3 was reduced by piceatannol in 
MCL cell lines (Supplemental Figure 4), while total Stat3 was reduced in Jeko-1 and UPN-1, but not significantly in Maver-1 
and Granta-519. According to these data, while the phosphorylation of Stat3 was reduced in all cell lines, the total level is 
reduced only in sensitive ones. Several publications support a role for Stat3 in the pathogenesis of MCL [48–52].
According to our data the down-regulation of CCND1 mRNA cannot explain the whole picture, since it was significant only in 
three cell lines after normalization using an unrelated transcript. An increase in Cyclin D1 degradation is another possible 
explanation, and might operate alongside transcription repression. In support of this complementary hypothesis is the reduction 
of GSK3 phosphorylation on negative regulatory serine residues, which increases its kinase activity with subsequent 
phosphorylation and degradation of Cyclin D1 [53].
SYK mRNA was significantly down-regulated by piceatannol treatment in UPN-1 and MAVER-1 (59% and 75% reduction; p = 
0.047 and p = 0.01 respectively). It was also reduced in Granta-519, but the values did not reach statistical significance (49% 
reduction; p = 0.11). SYK mRNA was increased after treatment in Jeko-1 and Mino (by 7% and 40% respectively) although 
values were not statistically significant (p = 0.8 and p = 0.32 respectively). Modifications of mRNA levels of SYK and CCND1
showed a good correlation with an r = 0.88 (Supplemental Figure 3).
Piceatannol-induced apoptosis involves the activation of the intrinsic pathway, and is accompanied by the 
modification of several regulators of cell cycle and apoptosis
Apoptosis was triggered trough the intrinsic pathway, involving Caspase 9 cleavage, as shown by western blotting experiments. 
Cleaved Caspase 8 levels were actually lower in the treated samples than in the untreated ones (not shown). Several apoptosis 
(Bcl-2, Bcl-xL, Bax, p53, p21), cell-cycle related (p53, p21, p27) molecules were investigated by western blotting. All 
investigated proteins showed the same behavior in all cell lines with the exception of Bax (Supplemental Figure 5). In detail, p53 
levels were increased after treatment (Jeko-1 resulted completely p53-negative due to the presence of a truncating mutation, 
while other cell lines with the exception of Granta-519 bear a missense mutation [54]); p21 was strongly down-regulated; p27 
was cleaved with a decrease of the 27 kDa isoform and increase of the 23KDa isoform; Bcl-2 was slightly increased, Bcl-xL was 
decreased, while Bax was increased in Jeko-1 and decreased in other cell lines. The mechanism inducing the increase of Bax (a 
pro-apoptotic Bcl-2 family member) in Jeko-1 is not clear, but this phenomenon might indicate a more pronounced perturbation 
of mitochondrial outer membrane potential [55]. The only clear-cut genomic abnormality that might suggest a stronger Syk-
dependance of Jeko-1 is the presence of the amplification of the SYK locus [6], although this cell line also bears a peculiar 
missense mutation of TP53 (in addition to a deletion of the other allele) that causes a premature stop codon with degradation of 
its mRNA [5], and at variance with other cell lines shows no p53 at all; this condition might cause an abnormal regulation of 
BAX, that is a known p53 target gene [56].
Piceatannol induces complex modifications of the Syk phosphorylation pattern and alterations of 
downstream effectors of the B-cell receptor pathway
To verify the effects of piceatannol on the pattern of phosphorylation of Syk and other BCR pathway members, we resorted to 
flow cytometry using phospho-specific antibodies. These experiments showed that piceatannol induced a marked decrease in 
phospho-Syk tyrosine residues Y525 and Y323, while unexpectedly the levels of Y352, which were almost negative in basal 
conditions, increased after treatment (Fig. 6). This residue resides in the linker region of Syk, in a stretch that is essential for 
nuclear localization, since a mutant lacking residues 332–359 was unable to enter the nucleus, as reported by a previous article 
[57]. These modifications were detectable after 6 h of treatment, but not after two (data not shown). As previously stated, B-CLL 
and DLBCL cells show a basal activation of Syk Y352, but no information is available for comparison about how this 
phosphorylation might be changed by Syk inhibition. 
Fig. 6
Modification of Syk phosphorylation profile following piceatannol treatment. After treatment, phosphorylation 
of residues Y525 and Y323 is reduced, while that of residue Y352 is increased. Red, untreated cells; blue, 
treated cells; solid grey, isotypic ...
The levels of the downstream effectors phospho-Blnk and phospho-Btk were also reduced by piceatannol treatment in Jeko-1 and 
to a lesser degree in MAVER-1 cells (Supplemental Figure 6).
To obtain independent information about the modifications of phospho-Syk after treatment, we used immunofluorescence 
microscopy. These experiments showed that in basal conditions phospho-Syk (Y525) is present in all cell lines tested, and is 
apparently confined to the cytoplasmic compartment of MCL cell lines (with the exception of Granta-519, that showed also a 
partial nuclear localization). After piceatannol treatment phospho-Syk (Y525) was down-regulated in the cytoplasm, but its 
presence could be demonstrated in the nucleus of MCL cell lines (Jeko-1, UPN-1, Mino, Granta-519, MAVER-1) (Fig. 7). This 
finding is in accordance with the reduction of phospho-Syk (Y525) detected by antibodies used in flow cytometry experiments, 
which were able to enter the cytoplasm but not the nucleus in our experimental conditions. 
Fig. 7
Localization of phospho-Syk following piceatannol treatment. P-Syk Y525 (shown in green pseudo-color) 
disappears from the cytoplasm and appears in the nucleus after treatment in all cell lines. Nuclei counter stained in 
blue pseudo-color (DAPI staining) ...
One possible hypothesis to explain this phenomenon is the fact that Syk has two known splice variants, of which only the longest 
is able to enter the nucleus [58]. Western blotting experiments in the five MCL cell lines Jeko-1, Granta-519, MAVER-1, UPN-1 
and Rec-1 showed that only one band was identifiable in the expected molecular weight range. A proteolytic 36 kDa isoform of 
Syk was also detected (data not shown), although the significance of this isoform described in erythrocytes [59], is still not clear 
in our cells, because it might be either a true functional variant or an experimental artifact. The absence of the shortest splice 
variant of Syk was also demonstrated by isoform-specific SYK RT-PCR experiments (Supplemental Figure 7). This was 
confirmed using two amplicons of different length as previously described [58]. The nuclear exclusion phenomenon therefore is 
probably not related to Syk differential splicing, but more probably to functional modifications of the protein, such as 
phosphorylation.
Conclusions
Our study has identified a large number of phosphorylated proteins and several activated pathways in MCL cells, which deserve 
a more thorough investigation by functional validation experiments. Our experimental data suggest that active BCR signaling is 
present in MCL cell lines and tumors, and that it plays a role in the survival of MCL cells; Syk is possibly one of the key 
molecules in this event, and it might have a double-face role in the cytoplasmic and nuclear compartments.
Our data also suggest that piceatannol, resveratrol or their analogues could represent a therapeutic option for patients with MCL 
if in vitro data will be confirmed in vivo.
Methods
Cell lines MCL cell lines Jeko-1, Granta-519 and Rec-1 were purchased from DSMZ (Braunschweig, Germany). Cell line 
MAVER-1 was developed in our laboratory [60]. Cell line Mino was obtained from ATCC (Manassas, VA, USA). UPN-1 cells 
were kindly provided by Dr. Elias Campo (Barcelona, Spain). Due to over-sensitivity to DMSO-induced apoptosis, Rec-1 cells 
were not used for apoptosis-induction assays.
Tumor samples Tumor samples were collected from the archives of the Department of Pathology and Diagnostics of the 
University of Verona. Informed consent had been collected for all patients and procedures were carried out according to the 
ethical guidelines of the University Hospital of Verona with the approval of an ethics committee, in compliance with the 
Helsinky Declaration.
PhosphoScan analysis PhosphoScan analysis was performed as previously described [23] on MCL cell lines MAVER-1, Granta-
519, Jeko-1, and Rec-1.The phospho-proteins identified using this analysis were categorized into KEGG Pathways using the 
DAVID Ease web framework [61]. For P-value and fold enrichment calculation the complete list of human genes was considered 
as a background. The calculation was repeated for lists obtained by selecting genes above the abundance cut-offs of 3, 4 and 
5.Illustrations were produced using the R statistical software package (http://www.r-project.org).
Flow cytometry Flow cytometric analysis of several tyrosine-phosphorylated forms of Syk (Y323, Y352 and Y525) and 
downstream target phospho-BLNK was performed as previously described [38] using antibodies shown in Table 2. All 
experiments were performed in triplicate. 
Table 2
Antibodies used in the study
RNA isolation and cDNA synthesis RNA isolation was performed using the Allprep DNA/RNA/Protein Mini Kit (Qiagen GmbH, 
Hilden, Germany), and RNA quality was assessed by using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, 
USA) and RNA 6000 Nano chips (Agilent Technologies). Each cDNA was synthesized from 1 μg total RNA using random 
primers and the Superscript III First-strand synthesis system (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
instructions.
RT-PCR The analysis of SYK isoforms was performed as previously described [58]. Reaction products were analyzed by the 
Agilent 2100 Bioanalyzer and the DNA1000 Chip (Agilent Technologies).
Quantitative RT-PCR Quantitative RT-PCR mRNA expression analysis was performed on ABI PRISM 7900HT Fast Real-time 
PCR System (Applied Biosystems, Foster City, CA) using Power SYBR green PCR Master Mix (Applied Biosystems). 
Oligonucleotide primers used were: CCND1-F AACTACCTGGACCGCTTCCT, and CCND1-R 
GGGGATGGTCTCCTTCATCT; TBP-F, GCACAGGAGCCAAGAGTGAA, and TBP-R, 
TCACAGCTCCCCACCATATT.TATA box binding protein (RefSeq ID NM_003194.3) transcript level was used to normalize 
SYK expression.Calibration curves for each couple of primers were obtained by serial dilution of cDNA. Expression data were 
analyzed by the comparative threshold cycle (Ct) method accordingly to User Bulletin No. 2 (Applied Biosystems). All 
experiments were performed in triplicate. The statistical significance of the data was investigated by Student’s t-test. All P values 
were two sided and considered significant when less than 0.05.
Syk inhibition experiments Piceatannol (Sigma-Aldrich Chemie GmBH, Steinheim, Germany) was resuspendend in DMSO as a 
100 mM stock. Cells were diluted at 500*10 /ml in RPMI 1640 (1% fetal calf serum) and let grow for 16 h. Piceatannol was then 
added at concentrations between 1 μM and 80 μM (depending on the sensitivity of cell lines). Cells were harvested at 24 and 
48 h and apoptosis levels analyzed by Annexin V (Annexin V–FITC apoptosis detection kit I, BD) as previously described [11]. 
All experiments were performed in triplicate.
Western blotting Immunoblotting was performed by standard methodology, using the antibodies and dilutions indicated Table 2.
Protein content of samples was measured using a colorimetric method (DC protein assay, Bio-Rad). All lanes were loaded with 
the same amount of total protein (in duplicate or triplicate), and were also visually verified by Ponceau red staining after 
electroblotting.
Immunofluorescence Immunofluorescence was performed using the antibodies shown in Table 2 (both primary and secondary 
antibodies were diluted 1:100). Briefly, cells were washed in PBS, deposited on charged slides by gravity, fixed in cold methanol 
(−20°C) for 20 min and then air-dried. Cells were then re-hydrated, incubated with protein blocking solution for 10′, then 
incubated serially with primary and secondary antibodies (with three washes in PBS in-between). Slides were examined under 
fluorescent light using an Olympus BX61 microscope. Images were acquired using appropriate filters via a monochromatic 
camera cooled CCD camera (iAi, Japan) and analyzed using the Olympus Cytovision software.
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Supplemental Figure 1
Basal levels of phospho-Lyn (Y396 and Y507), phospho-Btk (S180) and phospho-GSK3alfa/beta (S9/21) as analyzed by 
flow cytometry in MCL cells. In grey, isotypic control; in red, basal levels. On the X axis, arbitrary fluorescence units (log 
scale); on the Y axis, cell count. (JPEG 423 kb)
Supplemental Figure 2
Western blotting analysis of Cyclin D1 protein levels in piceatannol-treated cells. (JPEG 96 kb)
Supplemental Figure 3
Modifications of CCND1 and SYK mRNA after piceatannol treatment (normalized). A decrease of one ΔΔCt unit 
corresponds to a 50% reduction of RNA levels. A correlation plot between modifications of mRNA levels is also shown. 
(JPEG 536 kb)
Supplemental Figure 4
Western blotting analysis of modifications of levels of phospho-Stat3 (Y705) and Stat3 after piceatannol treatment in cell 
lines Jeko-1, UPN-1, Maver-1 and Granta-519. (JPEG 571 kb)
Supplemental Figure 5
Western blotting analysis of apoptosis-related and cell cycle-related molecules after exposure to piceatannol by western 
blotting. UPN-1 was totally BCL2-negative, while Jeko-1 showed no p53 protein due to a truncating mutation. (JPEG 
963 kb)
Supplemental Figure 6
Levels of phospho-Blnk and phospho-Btk after piceatannol treatment in cell lines Jeko-1 and MAVER-1 analyzed by flow 
cytometry. In grey, isotypic control; in red, basal levels, in blue, treated cells. On the X axis, arbitrary fluorescence units 
(log scale); on the Y axis, cell count. (JPEG 354 kb)
Supplemental Figure 7
Isoform-specific SYK RT-PCR experiments. Pseudo-gel image (upper panel) and two representative electropherograms 
(lower panel) of RT-PCR products are shown (images produced by microfluidic analysis). The absence of the shortest 
splice variant of Syk was demonstrated. (JPEG 348 kb)
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Complete list of peptides and complete MS information. (XLS 487 kb)
Supplemental Table 2
List of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched in MCL cell lines compared to random 
distribution. (XLS 28 kb)
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LD50 of piceatannol at 24 and 48 h for MCL cell lines. (XLS 6 kb)
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Number of identified phospho-peptides corresponding to members of the KEGG BCR pathway in the four tested MCL cell 
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